Dipeptidyl peptidase IV inhibitors for the treatment of diabetes

被引:259
作者
Weber, AE [1 ]
机构
[1] Merck Res Labs, Rahway, NJ 07065 USA
关键词
D O I
10.1021/jm030628v
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
引用
收藏
页码:4135 / 4141
页数:7
相关论文
共 85 条
[21]   Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide [J].
Deacon, CF ;
Nauck, MA ;
Meier, J ;
Hücking, K ;
Holst, JJ .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2000, 85 (10) :3575-3581
[22]   BOTH SUBCUTANEOUSLY AND INTRAVENOUSLY ADMINISTERED GLUCAGON-LIKE PEPTIDE-I ARE RAPIDLY DEGRADED FROM THE NH2-TERMINUS IN TYPE-II DIABETIC-PATIENTS AND IN HEALTHY-SUBJECTS [J].
DEACON, CF ;
NAUCK, MA ;
TOFTNIELSEN, M ;
PRIDAL, L ;
WILLMS, B ;
HOLST, JJ .
DIABETES, 1995, 44 (09) :1126-1131
[23]   Vivo inhibition of dipeptidyl peptidase IV activity by pro-pro-diphenyl-phosphonate (prodipine) [J].
DeMeester, I ;
Belyaev, A ;
Lambeir, AM ;
DeMeyer, GRY ;
VanOsselaer, N ;
Haemers, A ;
Scharpe, S .
BIOCHEMICAL PHARMACOLOGY, 1997, 54 (01) :173-179
[24]  
Demuth H U, 1988, J Enzyme Inhib, V2, P129, DOI 10.3109/14756368809040718
[25]  
Demuth HU, 2000, DIABETES, V49, pA102
[26]  
DESIMONE RW, 2000, Patent No. 0059887
[27]   Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes [J].
Drucker, DJ .
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2003, 12 (01) :87-100
[28]   The crystal structure of dipeptidyl peptidase IV(CD26) reveals its functional regulation and enzymatic mechanism [J].
Engel, M ;
Hoffmann, T ;
Wagner, L ;
Wermann, M ;
Heiser, U ;
Kiefersauer, R ;
Huber, R ;
Bode, W ;
Demuth, HU ;
Brandstetter, H .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (09) :5063-5068
[29]  
GLUND K, 2000, EXP CLIN ENDOCRINOL, V108, P159
[30]  
Hansotia T, 2003, DIABETES, V52, pA77